Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Operating activities
Net loss	$ (38,871)	$ (103,315)
Adjustments to reconcile net loss to net cash used in by operating activities:
Gain on forgiveness of PPP Loan	0	(257)
Acquired in-process research and development	0	84,478
Purchased in-process research and development	0	4,000
Share-based compensation expense	11,374	3,734
Depreciation and amortization	153	119
Amortization of premiums and accretion of discounts on short-term investments, net	(175)	0
Change in fair value of preferred stock warrant liability	0	290
Change in operating assets and liabilities:
Prepaid expenses and other assets	(894)	(1,359)
Other assets	425	743
Accounts payable	(1,285)	118
Accrued expenses	1,592	(203)
Lease liabilities, net	(3)	12
Other long-term liabilities	130	0
Net cash used in operating activities	(27,554)	(11,640)
Investing activities
Purchase of property and equipment	(45)	(233)
Purchased in-process research and development	0	(4,000)
Purchases of short-term investments	(54,418)	0
Proceeds from maturity of short-term investments	800
Cash acquired in connection with the Merger	0	17,143
Net cash (used in) provided by investing activities	(53,663)	12,910
Financing activities
Issuance of common stock, net of issuance costs	1,034	62,320
Exercise of warrants and stock options to purchase common stock	101	304
Net cash provided by financing activities	1,135	62,624
Net increase (decrease) in cash and cash equivalents	(80,082)	63,894
Cash and cash equivalents at beginning of period	103,554	47,089
Cash and cash equivalents at end of period	23,472	110,983
Supplemental disclosure of cash flow information
Interest paid	332	257
Noncash financing activities
Warrant liability reclassification to equity	0	396
Issuance of convertible preferred stock upon merger	0	5,452
Conversion of convertible preferred stock into common stock upon Merger	0	83,302
Issuance of common stock upon Merger	$ 0	$ 97,982